180 Life Sciences Announces Review of Strategic Alternatives
PALO ALTO, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that its Board of Directors has initiated a process to evaluate potential strategic alternatives with the intent to unlock and maximize shareholder value. In consultation with financial and legal advisors, the Company intends to consider a broad range of strategic, operational and financial alternatives, and is exploring a full range of options.
There is no assurance that the strategic review process will result in the approval or completion of any specific transaction or outcome.
180 Life Sciences has not established a timeline for completion of the review process and does not intend to comment further unless and until its Board of Directors has approved a definitive course of action, or it is determined that other disclosure is necessary or appropriate.
Recent ATNF News
- 180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price Requirement • GlobeNewswire Inc. • 03/14/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/11/2024 11:03:16 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/08/2024 09:49:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 01:00:09 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 02/28/2024 11:42:18 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 02/28/2024 11:39:40 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 02/28/2024 11:37:05 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 11:30:47 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2024 12:00:18 PM
- 180 Life Sciences Corp. Announces 1-For 19 Reverse Stock Split as Part of Nasdaq Compliance Plan • GlobeNewswire Inc. • 02/26/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/20/2024 01:01:20 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 02/16/2024 10:10:53 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 02/16/2024 10:08:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 02/16/2024 10:05:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:15:23 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 02/12/2024 09:15:26 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 01/31/2024 10:29:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/29/2024 01:00:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/17/2024 01:30:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2024 01:30:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/28/2023 11:42:49 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 12/27/2023 09:15:23 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/26/2023 09:15:04 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/21/2023 10:00:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/20/2023 01:00:26 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM